Company profile: Novavax
1.1 - Company Overview
Company description
- Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
Products and services
- Matrix-M adjuvant technology: Saponin-based technology that enhances immune response and improves vaccine efficacy, acting as an adjuvant to amplify immunogenicity in recombinant nanoparticle vaccines
- Novavax COVID-19 vaccine: Recombinant nanoparticle-based vaccine employing Matrix-M adjuvant to prevent COVID-19 by presenting genetically engineered protein particles that mimic the virus and enhance immune response
- Recombinant nanoparticle vaccine technology: Genetically engineered platform that produces vaccines using recombinant protein nanoparticles to mimic viruses and enhance immune response, supporting development of disease-preventing vaccine products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novavax
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Virometix
HQ: Switzerland
Website
- Description: Provider of a new generation of vaccines and immunotherapeutic drugs for preventing and treating infectious and chronic human diseases, including V-212 for Streptococcus pneumoniae, V-306 for RSV, coronavirus and cancer vaccines, built on a modular synthetic virus-like particle (SVLP) platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Virometix company profile →
Numab Therapeutics
HQ: Switzerland
Website
- Description: Provider of antibody-based therapeutics for severe diseases, including chronic inflammation and cancer, leveraging a plug-and-play platform to predictably yield ready-to-develop multispecific biotherapeutics. Offerings include NM26 for atopic dermatitis, NM49 for cancer, and λ-Cap (stable human antibody fragments) and MATCH (modular scaffolding for multispecific formats) technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Numab Therapeutics company profile →
Vitaeris
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical development by a Canadian company focused on the anti-interleukin-6 monoclonal antibody Clazakizumab, with global exclusive rights licensed from Alder Biopharmaceuticals, pursuing applications in chronic inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitaeris company profile →
Kairos Therapeutics
HQ: Canada
Website
- Description: Provider of a proprietary next-generation antibody-drug conjugate platform as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kairos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novavax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novavax
2.2 - Growth funds investing in similar companies to Novavax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novavax
4.2 - Public trading comparable groups for Novavax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →